#COSMIC312 - Twitter Hashtag

almost 4 years ago

@TumorBoardTues @BonumCe @rachnatshroff @DJPinato @MPishvaian @GABOUALFA @marinabaretti @marklewismd @US_FDA @DrJNaidoo @cappelliMD @JulieBrahmer @DanengLi @llovet_m @LorenzaRimassa 14/ #TumorBoardTuesday #COSMIC312 - cabo + atezo vs sorafenib ⬆️ in PFS but not OS ⚠️ G3/4 TRAEs: 64% vs 46% ⚠️ Discont due to TRAEs: 14% vs 8% ⚠️No excess of serious bleeding events in cabo arm despite no requirement for endoscopy prior to enrollment ⚠️ Common G3/4 TRAEs 👇

MarkYarchoan's tweet photo. @TumorBoardTues @BonumCe @rachnatshroff @DJPinato @MPishvaian @GABOUALFA @marinabaretti @marklewismd @US_FDA @DrJNaidoo @cappelliMD @JulieBrahmer @DanengLi @llovet_m @LorenzaRimassa 14/ #TumorBoardTuesday

#COSMIC312 - cabo + atezo vs sorafenib
⬆️ in PFS but not OS

⚠️ G3/4 TRAEs: 64% vs 46%
⚠️ Discont due to TRAEs: 14% vs 8%
⚠️No excess of serious bleeding events in cabo arm despite no requirement for endoscopy prior to enrollment
⚠️ Common G3/4 TRAEs 👇 https://t.co/FgUbwlfTE6

1

4

2

0

HCC CONNECT powered by COR2ED

@hccconnectinfo

almost 4 years ago

#ILCA2022, Systemic therapy guidance talk ongoing with Tim Meyer & Robin Kate Kelley. Important clinical practice questions to address with recent/upcoming results from Phase 3 trials: #COSMIC312, #HIMALAYA, #LEAP002, #RATIONALE301 & Camrelizumab+rivoceranib in 1L #HCC #MedEd

hccconnectinfo's tweet photo. #ILCA2022, Systemic therapy guidance talk ongoing with Tim Meyer & Robin Kate Kelley.
Important clinical practice questions to address with recent/upcoming results from Phase 3 trials: #COSMIC312, #HIMALAYA, #LEAP002, #RATIONALE301 & Camrelizumab+rivoceranib in 1L #HCC #MedEd https://t.co/emqyqQQOzl

1

5

1

0

Lorenza Rimassa @LorenzaRimassa

over 4 years ago

#COSMIC312 phase 3 trial of cabozantinb + atezolizumab vs sorafenib in first-line #HCC presented by #KatieKelley at #ESMOVirtualPlenary #ESMOasiaweek21. Improved #PFS, but not yet #OS. Also data on #cabozantinb single-agent @myESMO

LorenzaRimassa's tweet photo. #COSMIC312 phase 3 trial of cabozantinb + atezolizumab vs sorafenib in first-line #HCC presented by #KatieKelley at #ESMOVirtualPlenary #ESMOasiaweek21. Improved #PFS, but not yet #OS. Also data on #cabozantinb single-agent @myESMO https://t.co/PKb7w1Uwqg

1

33

9

2

0

Evaluate Japan @EvaluateJP

about 5 years ago

#Cabometyx の適応拡大が頓挫したことで、#Exelixis 社は新たな成長戦略を模索し始めた。挫折したのは #Cosmic312 のデータで、肝がんの前治療で生存率の改善が見られなかった。競合他社の脅威が高まるなか、他のがん種で成果を上げる必要がある。 https://t.co/878P2MIqRK #エバリュエート

EvaluateJP's tweet photo. #Cabometyx の適応拡大が頓挫したことで、#Exelixis 社は新たな成長戦略を模索し始めた。挫折したのは #Cosmic312 のデータで、肝がんの前治療で生存率の改善が見られなかった。競合他社の脅威が高まるなか、他のがん種で成果を上げる必要がある。
https://t.co/878P2MIqRK
#エバリュエート https://t.co/hRPvvTW7Zz

0

3

2

0

Lorenza Rimassa @LorenzaRimassa

almost 7 years ago

Another video from #ESMO19 about the #COSMIC312 trial of #cabozantinib plus #atezolizumab for advanced #HCC @myESMO #CongressReport https://t.co/pTv1hHpIfn

0

6

1

0

Top Tweets for #COSMIC312

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users